143 related articles for article (PubMed ID: 15018237)
1. Immunomodulation effects and clinical evidence of apheresis in renal diseases.
Yokoyama H; Wada T; Furuichi K
Ther Apher Dial; 2003 Dec; 7(6):513-9. PubMed ID: 15018237
[TBL] [Abstract][Full Text] [Related]
2. Advances in apheresis therapy for glomerular diseases.
Yokoyama H; Wada T; Zhang W; Yamaya H; Asaka M
Clin Exp Nephrol; 2007 Jun; 11(2):122-127. PubMed ID: 17593511
[TBL] [Abstract][Full Text] [Related]
3. Apheresis for Kidney Disease.
Furuichi K; Wada T
Contrib Nephrol; 2018; 196():188-193. PubMed ID: 30041226
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic apheresis for renal diseases.
Harada T; Miyazaki M; Ozono Y; Sasaki O; Shioshita K; Kohno S; Nishikido M; Saito Y; Taguchi T
Ther Apher; 1998 Aug; 2(3):193-8. PubMed ID: 10227769
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic apheresis in renal and metabolic diseases.
Winters JL; Pineda AA; McLeod BC; Grima KM
J Clin Apher; 2000; 15(1-2):53-73. PubMed ID: 10767051
[No Abstract] [Full Text] [Related]
6. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy.
Sułowicz W; Stompór T
Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v59-62. PubMed ID: 12817074
[TBL] [Abstract][Full Text] [Related]
7. The use of apheresis in immune renal disorders.
Kaplan AA
Ther Apher Dial; 2003 Apr; 7(2):165-72. PubMed ID: 12918939
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome.
Yokoyama H; Shimizu M; Wada T; Yoshimoto K; Iwata Y; Shimizu K; Sakai N; Furuichi K; Hisada Y; Takakuwa H; Kobayashi K
Ther Apher; 2002 Apr; 6(2):167-73. PubMed ID: 11982960
[TBL] [Abstract][Full Text] [Related]
9. A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis.
Kamijo Y; Kaneko Y; Ichikawa T; Kobayashi N; Koyama T; Kakegawa T; Kamijo H; Kono K; Minami S; Tanaka N; Arakura H; Hirata M; Higuchi M; Kiyosawa K; Hora K
Ther Apher; 2002 Dec; 6(6):459-62. PubMed ID: 12460411
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic apheresis for renal disorders.
Sanchez AP; Ward DM
Semin Dial; 2012; 25(2):119-31. PubMed ID: 22428811
[TBL] [Abstract][Full Text] [Related]
11. [Circulating immune complexes in glomerulonephritis patients].
Diadyk AI; Siniachenko OV; Nikolenko IuI; Iarovaia NF; Khomenko MV
Vrach Delo; 1986 Aug; (8):94-7. PubMed ID: 3776174
[No Abstract] [Full Text] [Related]
12. [Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions].
Haris A; Arányi J; Braunitzer H; Kálmán E; Merán Z; Soltész M; Polner K
Orv Hetil; 2011 Jul; 152(28):1110-9. PubMed ID: 21712172
[TBL] [Abstract][Full Text] [Related]
13. Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy.
Tanaka A; Nakamura T; Sato E; Node K
Nephrology (Carlton); 2016 Dec; 21(12):1073-1074. PubMed ID: 27870230
[No Abstract] [Full Text] [Related]
14. Plasticity and heterogeneity of Th17 in immune-mediated kidney diseases.
Krebs CF; Panzer U
J Autoimmun; 2018 Feb; 87():61-68. PubMed ID: 29275837
[TBL] [Abstract][Full Text] [Related]
15. Apheresis for renal disease.
Kaplan AA
Ther Apher; 2001 Apr; 5(2):134-41. PubMed ID: 11354298
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein apheresis for proteinuria in lupus nephritis with intraglomerular foam cells containing cholesterol crystals.
Shiraishi N; Kitamura K; Hayata M; Ogata T; Tajiri-Okamura K; Nakayama Y; Kohda Y; Tomita K; Mukoyama M
Am J Kidney Dis; 2015 Mar; 65(3):490-3. PubMed ID: 25542412
[TBL] [Abstract][Full Text] [Related]
17. [Intractable renal vasculitis by lupus nephritis and ANCA associated vasculitis].
Yoshida M
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Jun; 27(3):137-44. PubMed ID: 15291250
[No Abstract] [Full Text] [Related]
18. [Is apheresis still a useful tool in the treatment of nephrological diseases?].
Santoro A
G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983168
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
Tojo K; Sakai S; Miyahara T
Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
[No Abstract] [Full Text] [Related]
20. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis.
Esnault VL; Testa A; Jayne DR; Soulillou JP; Guenel J
Nephron; 1993; 65(2):180-4. PubMed ID: 8247177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
